- Home
- CGBD vs OCS Comparison
CGBD vs OCS Comparison
Compare CGBD & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- OCS
- Stock Information
- Founded
- CGBD 2012
- OCS 2003
- Country
- CGBD United States
- OCS Switzerland
- Employees
- CGBD N/A
- OCS N/A
- Industry
- CGBD Finance: Consumer Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- OCS Health Care
- Exchange
- CGBD Nasdaq
- OCS Nasdaq
- Market Cap
- CGBD 881.4M
- OCS 869.8M
- IPO Year
- CGBD 2017
- OCS N/A
- Fundamental
- Price
- CGBD $12.79
- OCS $21.55
- Analyst Decision
- CGBD Hold
- OCS Strong Buy
- Analyst Count
- CGBD 5
- OCS 4
- Target Price
- CGBD $14.25
- OCS $41.00
- AVG Volume (30 Days)
- CGBD 625.3K
- OCS 85.4K
- Earning Date
- CGBD 11-04-2025
- OCS 11-06-2025
- Dividend Yield
- CGBD 12.37%
- OCS N/A
- EPS Growth
- CGBD N/A
- OCS N/A
- EPS
- CGBD 1.14
- OCS N/A
- Revenue
- CGBD $234,464,000.00
- OCS $960,668.00
- Revenue This Year
- CGBD $15.09
- OCS $38.85
- Revenue Next Year
- CGBD $5.69
- OCS $994.06
- P/E Ratio
- CGBD $11.18
- OCS N/A
- Revenue Growth
- CGBD N/A
- OCS N/A
- 52 Week Low
- CGBD $11.65
- OCS $14.00
- 52 Week High
- CGBD $18.64
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CGBD 53.02
- OCS 64.29
- Support Level
- CGBD $12.36
- OCS $20.91
- Resistance Level
- CGBD $13.05
- OCS $21.84
- Average True Range (ATR)
- CGBD 0.28
- OCS 0.65
- MACD
- CGBD 0.12
- OCS -0.07
- Stochastic Oscillator
- CGBD 81.43
- OCS 67.63
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.